VINC
PINK Vincerx Pharma Inc$0.0257 ↑ +0.0107 (+71.33%) Trading Up from the previous close of $0.0150, and at the day’s high of $0.0257
- YTD change
- +105.60%
- vs 20-day SMA
- +90.44%
- vs 200-day SMA
- +46.34%
Price ranges
Price & Performance
+0.00 (+18.11%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 100.0% away from all-time highs of $535.0000
- VINC is up 106% since the beginning of the year
- VINC is down 61% over the past 12 months
- VINC is up 102% over the past 1 month
- 0% of all VINC investors are betting against VINC
VINC reads n/a: price sits above both the 20- and 200-day averages, the 12-month move is -70.5%.
- Previous minute
- +$0.0000
- Last hour
- +$0.0107
- Last 5 days
- +71.33%
- vs 8-day SMA
- +71.33%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. It focuses on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The firm pipeline is derived from a license agreement with Bayer and includes: a clinical-stage and follow-on small molecule drug program and preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. The company was founded by Ahmed M. Hamdy, Raquel E. Izumi, Tom C. Thomas, Soo In Hwang and John C. Byrd on December 19, 2018 and is headquartered in Palo Alto, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
